GLPwatch
The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.
J Pharm Technol · 2024
Last updated 2026-07-22Retatrutide is a new drug being studied for obesity that targets three hormones. In phase II trials, participants lost up to 24% of their body weight and nearly 20 cm from their waist. The most common side effects were related to the stomach and intestines. More research is underway to assess its safety and effectiveness.
AI summary of the abstract below.
| Journal | J Pharm Technol, 2024 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | retatrutide |
| Conditions studied | Obesity |
Abstract
Retatrutide, a hormone receptor agonist targeting glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide, is being developed to treat obesity. A literature review from April 2019 to April 2024 included such terms as "retatrutide," "LY3437943," "overweight," and "obesity." Phase I proof-of-concept studies led to phase II trials showing up to 24% body weight reduction and nearly 20 cm waist circumference reduction. The most common adverse effects were gastrointestinal. Ongoing phase II and III studies aim to further evaluate the safety and efficacy of retatrutide as a novel triagonist for obesity treatment.
Verbatim abstract via PubMed 39507873 ↗
Related research
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
- The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.